
Sarah Anderson
Articles
-
2 months ago |
ajmc.com | Pearl Steinzor |Sarah Anderson
The genetic diversity in the Asia-Pacific region is crucial for personalized treatment approaches and the development of novel biomarkers, addressing the urgent clinical need for innovative treatments in regions with limited access to standard care for patients with triple-negative breast cancer (TNBC), says Sarah Anderson, oncology strategy lead director, Novotech. This transcript has been lightly edited for clarity; captioning was auto generated.
-
2 months ago |
ajmc.com | Pearl Steinzor |Sarah Anderson
The growing prevalence in the Asia-Pacific region of triple-negative breast cancer (TNBC) signifies a shift toward a more inclusive and globally balanced research landscape, says Sarah Anderson, oncology strategy lead director, Novotech. This transcript has been lightly edited for clarity; captioning was auto generated. Transcript What accounts for the growing prominence of the Asia-Pacific region in TNBC clinical trials, and how might this shift influence global research priorities?
-
Dec 30, 2024 |
oncozine.com | Sarah Anderson
Cervical cancer remains one of the most preventable yet devastating diseases affecting women worldwide. Despite remarkable advances in prevention and treatment, the global burden of cervical cancer continues to highlight stark disparities in healthcare access, education, and resources. As we approach 2050, projections suggest a 40% increase in cervical cancer cases globally, underscoring the urgent need for coordinated, data-driven interventions.
-
Oct 11, 2024 |
neurologylive.com | Sarah Anderson |Isabella Ciccone
CommentaryArticleOctober 11, 2024Author(s):Fact checked by:Sarah Anderson, PharmD, NBC-HWC, senior director of clinical resources and programming at National MS Society, talked about the significant updates under the Inflation Reduction Act to come in 2025 for patients with multiple sclerosis. The Inflation Reduction Act (IRA), signed into law in August 2022, introduced pivotal reforms aimed at addressing high prescription drug costs, particularly for Medicare beneficiaries.
-
Oct 10, 2024 |
neurologylive.com | Sarah Anderson |Isabella Ciccone
WATCH TIME: 9 minutes"Beginning January 1, 2025, the Inflation Reduction Act caps annual out-of-pocket costs for Part D beneficiaries at $2,000, providing much-needed relief for many living with chronic conditions like MS."The Inflation Reduction Act (IRA), signed into law in August 2022, aimed to address various healthcare concerns, specifically high prescription drug prices.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →